文献速递青光眼白内障与屈光手术

低剂量经巩膜睫状体光凝联合超声乳化治疗持续性急性原发性闭角型青光眼

Low-dose transscleral cyclophotocoagulation with subsequent phacoemulsification in the treatment of prolonged acute primary angle closure.
PubMed 文献 · Br J Ophthalmol · 2021-08-30

该前瞻性研究纳入20眼持续性急性原发性闭角型青光眼(APAC),先行低剂量经巩膜睫状体光凝(LDTSCP)再行超声乳化联合人工晶体植入及黏弹剂房角分离。中位随访12个月时所有眼视力改善且眼压≤17 mmHg(无需降眼压药)。LDTSCP后早期眼压下降与光凝爆破次数多及脉络膜上腔积液(SCE)分级高相关。

要点

  • LDTSCP后早期眼压下降与SCE分级高及爆破次数多相关,与总能量无关。
  • 中位随访12个月所有眼视力改善且眼压≤17 mmHg,无需降眼压药。
  • LDTSCP可作为持续性APAC患者超声乳化术前相对安全有效的桥接治疗。

核心结论

  • LDTSCP诱导的SCE可能解释持续性APAC眼LDTSCP后眼压下降。
  • LDTSCP替代传统更广泛治疗,足以作为超声乳化术前相对安全有效的桥接疗法。

研究设计与样本

  • 前瞻性招募对其他所有治疗方式难治的持续性APAC患者。
  • LDTSCP参数:10个光凝点,每次2秒,120°治疗,能量起始1500 mW并滴定至有 audible burst 但不超2000 mW。
  • LDTSCP后1周行超声乳化联合人工晶体植入及黏弹剂房角分离。
  • 共纳入20眼,中位随访12个月(范围9-18个月)。

主要发现

  • LDTSCP后第1天所有眼眼压降至中位15 mmHg(范围6-28 mmHg)。
  • LDTSCP后第1天或第7天90%眼出现SCE,30%眼检出睫状体缺损(CBD)且术后1个月均消退。
  • LDTSCP后眼压较低与爆破次数多(r=-0.558,p=0.011)及SCE分级高(r=-0.877,p<0.001)相关,与总能量无关(p=0.240)。
  • 有CBD的眼(p=0.018)及爆破次数多的眼(r=0.657,p=0.002)SCE分级更高。
  • 中位随访12个月时所有眼视力改善且眼压≤17 mmHg,无需降眼压药。

关键数值与推荐

  • LDTSCP能量起始1500 mW,滴定至有 audible burst 但不超2000 mW。
  • 随访12个月时眼压≤17 mmHg且无需抗青光眼药物。

临床怎么用

  • 对持续性APAC且对其他治疗难治者,可考虑LDTSCP作为超声乳化术前桥接治疗。
  • LDTSCP后早期出现SCE或CBD可能提示眼压下降效果,需监测前节OCT变化。

局限性

  • 样本量小(20眼),随访时间有限(中位12个月,范围9-18个月)。
  • 为前瞻性单臂研究,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To explore the outcomes and mechanisms of intraocular pressure (IOP) control using low-dose transscleral cyclophotocoagulation (LDTSCP) followed by phacoemulsification in patients with prolonged acute primary angle closure (APAC). METHODS: Patients with prolonged APAC refractory to all other treatment modalities were prospectively recruited, and underwent LDTSCP (10 shots, 2 s duration, 120° treatment with the energy starting at 1500 mW and titrated to the level with audible burst but not exceeding 2000 mW) and anterior chamber paracentesis 1 week prior to phacoemulsification with intraocular lens implantation and viscogoniosynechiolysis. Postoperative IOP, vision, anatomic changes on anterior segment optical coherence tomography and complications were recorded. RESULTS: Twenty eyes with prolonged APAC were recruited. Median follow-up was 12 months (range 9-18), at which point the vision in all eyes had improved and IOP was ≤17 mm Hg on no antiglaucoma medications. Following LDTSCP at postoperative day (POD) 1, IOP decreased in all eyes to a median 15 mm Hg (range: 6-28 mm Hg). Post-LDTSCP supraciliary effusion (SCE) occurred in 90% of eyes on POD1 or POD7 and ciliary body defect (CBD) was detected in 30% of eyes and resolved in all cases by postoperative month 1. Lower post-LDTSCP IOP was associated with more number of bursts (r=-0.558, p=0.011) and higher grade of SCE (r=-0.877, p<0.001), but not with total energy (p=0.240). Eyes with CBD (p=0.018) and a higher number of bursts (r=0.657, p=0.002) had higher grade SCE. CONCLUSIONS: LDTSCP-induced SCE may explain the post-LDTSCP IOP reduction seen in eyes with prolonged APAC. LDTSCP instead of traditional more extensive treatment, was sufficient to provide a relatively safe and effective bridge therapy prior to phacoemulsification. TRIAL REGISTRATION NUMBER: Chinese Clinical Trials Registry (ChiCTR1900023567).

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shi Y, Oatts J, Tian J, et al. Low-dose transscleral cyclophotocoagulation with subsequent phacoemulsification in the treatment of prolonged acute primary angle closure. Br J Ophthalmol. 2021. PMID: 34462269. doi:10.1136/bjophthalmol-2021-318880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。